The field of regenerative medicine faces challenges in efficiently and compliantly managing the entire process of tissue engineering, from sourcing and processing to distribution and application. Current solutions often lack comprehensive integration, hindering the development and delivery of effective cell and tissue therapies.

Tiger BioSciences operates as a vertically integrated company focused on regenerative medicine, encompassing tissue engineering, processing, and compliant distribution of cell and tissue therapies. Through its subsidiaries, the company manages the entire product lifecycle, from initial research and development to clinical applications. By maximizing the potential of human tissue donations, Tiger BioSciences aims to provide innovative products that support the healing process and improve patient outcomes in wound care, aesthetics, and other chronic conditions. The company's approach ensures quality control and regulatory compliance throughout the tissue engineering process.

Vertical integration encompassing tissue engineering, processing, and compliant distribution

Portfolio of subsidiary companies focused on specific areas within regenerative medicine, including Extremity Care, RegenTX, and BioCreations Medical

Advanced research and processing techniques to maximize the potential of human tissue donations

careLOG™ shipping logistics solution for compliant handling of cell and tissue products

Focus on developing innovative regenerative therapy products for wound care, aesthetics, and other chronic conditions

Comprehensive portfolio of Sientra brand medical devices and advanced adipose tissue technologies through Tiger Aesthetics

The primary target audience includes healthcare providers, medical facilities, and patients seeking advanced cell and tissue therapies for wound care, regenerative medicine, and aesthetic applications.